Common Stock
- Symbol
- TWST
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
TWSTNASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition. On May 4, 2026, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.
Twist Bioscience Corporation · 8-K · Filed 2026-05-04
EX-99.1 2 twst-2026331xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results - Record revenue of $110.7 million in 2QFY26; Increase of more than 19% over $92.8 million in 2QFY25; 13th consecutive quarter of sequential growth - - Gross margin of 51.6% in 2QFY26; Improvement of approximately 2 margin points versus 2QFY25 - - Revenue guidance raised to $442-$447M; Reiterating Q4 FY26 Adj EBITDA breakeven - SOUTH SAN FRANCISCO, Calif. -- (May 4, 2026) - Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today reported financial results and business highlights for the second quarter ended March 31, 2026. "We had a strong performance in the first half of fiscal 2026, ending the second quarter with our thirteenth consecutive quarter of growth. Revenue exceeded guidance, coming in at $110.7 million, growth of over 19% compared to the second quarter of 2025," said Emily M. Leproust, Ph. D., CEO and co-founder of Twist Bioscience. "As we look ahead, we remain focused on delivering consistent, measurable growth designed to scale over time. We expect to chart toward profitability while simu…
Open exhibit ↗